



July 25, 2006

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Category	Type of Change
I.	Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements
II.	Tests that have been discontinued
III.	Tests that have had changes to their reference comment

Please be advised that the changes listed in this packet will go into effect on **December 4, 2006**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

We apologize if this causes you any inconvenience. If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

Sincerely,

NMS Labs

## Database Changes - Summary

**Categories:**

- I: Method/CPT Code, Units, Scope of Analysis and Specimen Requirements
- II: Deleted tests
- III: Reference comment changes

Test Code	Test Name	Category		
		I	II	III
0451B	Aripiprazole, Blood			•
0451SP	Aripiprazole, Serum/Plasma			•
0451U	Aripiprazole, Urine			•
0486SP	Atomoxetine, Serum/Plasma			•
0486U	Atomoxetine, Urine			•
0717B	Brodifacoum, Blood			•
0717SP	Brodifacoum, Serum/Plasma			•
2053U	Ethylene Glycol Monobutyl Ether, Urine	•		
3063SP	Mycophenolic Acid and Metabolite, Serum/Plasma			•
3107U	Nabumetone as Metabolite, Urine			•
3795U	Pregabalin, Urine			•
4213U	Styrene Exposure Profile, Urine	•		
4666B	Duloxetine, Blood			•
4666SP	Duloxetine, Serum/Plasma			•
4822U	Xylenes Exposure Monitoring Survey, Urine	•		
5525B	Fluphenazine Confirmation, Blood			•
5525SP	Fluphenazine Confirmation, Serum/Plasma			•
5557U	Oxycodone and Metabolite Confirmation - Total (Conjugated/Unconjugated), Urine	•		
5900H	Cocaine Confirmation, Hair	•		
9288U	Tramadol and Metabolite Screen, Urine		•	
9421B	Fluphenazine Screen, Blood			•
9421SP	Fluphenazine Screen, Serum/Plasma			•
9440U	Meperidine and Metabolite Screen, Urine		•	

**NMS Labs**

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Changes effective:  
December 4, 2006

**NMS Labs**  
3701 Welsh Road, Willow Grove, PA 19090  
800-522-6671  
nms@nmslabs.com

## TEST CHANGES

### Method/CPT Code, Units of Measurement, Scope of Analysis and Specimen Requirements

Test Code	Test Name / Compounds	Method/CPT Code Changes	Unit Changes
5900H	<b>Cocaine Confirmation, Hair</b> <ul style="list-style-type: none"> <li>Cocaine</li> <li>Cocaethylene</li> <li>Benzoyllecgonine</li> </ul> <b>Method of analysis was changed to GC/MS. Test Name was changed.</b>	GC/MS GC/MS GC/MS	
2053U	<b>Ethylene Glycol Monobutyl Ether, Urine</b> <ul style="list-style-type: none"> <li>Creatinine</li> <li>Butoxyacetic Acid</li> <li>Butoxyacetic Acid (Creatinine corrected)</li> </ul> <b>Units of measurement were changed for Butoxyacetic acid.</b>		mcg/mL
5557U	<b>Oxycodone and Metabolite Confirmation - Total (Conjugated/Unconjugated), Urine</b> Scope of Analysis: Oxycodone - Total, Oxymorphone - Total <b>Oxycodone - Free and Oxymorphone - Free were removed.</b> <b>Oxycodone - Total [ng/mL; GC/MS] and Oxymorphone - Total [ng/mL; GC/MS] were added.</b> <b>Test Name was changed.</b>		
4213U	<b>Styrene Exposure Profile, Urine</b> Scope of Analysis: Mandelic Acid, Mandelic Acid (Creatinine corrected), Creatinine, Phenylglyoxylic Acid, Phenylglyoxylic Acid (Creatinine corrected) <b>Mandelic Acid (Creatinine correction) and Phenylglyoxylic Acid (Creatinine correction) were removed.</b> <b>Mandelic Acid (Creatinine corrected) [g/g Creat; IC] and Phenylglyoxylic Acid (Creatinine corrected) [g/g Creat; IC] were added.</b>		
4822U	<b>Xylenes Exposure Monitoring Survey, Urine</b> Scope of Analysis: Methylhippuric Acid, Methylhippuric Acid (Creatinine corrected), Creatinine <b>Methylhippuric Acid (Creatinine correction) was removed.</b> <b>Methylhippuric Acid (Creatinine corrected) [g/g Creat; IC] was added.</b>		

## DISCONTINUED TESTS

Test Code	Test Name	Alternative Test
9288U	Tramadol and Metabolite Screen, Urine	9287U Tramadol Screen, Urine
9440U	Meperidine and Metabolite Screen, Urine	9444U Meperidine Screen, Urine

**REFERENCE COMMENT CHANGES**

<b>Test Code</b>	<b>Test Name / Compound</b>	<b>New Reference Comment</b>
<b>0717B</b>	<b>Brodifacoum, Blood</b> <ul style="list-style-type: none"> <li>Brodifacoum</li> </ul>	<p>Within 24 hours of exposure, approximately 90% of Brodifacoum is found in the liver.</p> <p>The elimination is slow, with a terminal phase half-life in humans of 20 to 62 days reported in three cases. Anticoagulation effects have been reported in canine serum at concentrations as low as 12 ng/mL.</p>
<b>0717SP</b>	<b>Brodifacoum, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Brodifacoum</li> </ul>	<p>Within 24 hours of exposure, approximately 90% of Brodifacoum is found in the liver.</p> <p>The elimination is slow, with a terminal phase half-life in humans of 20 to 62 days reported in three cases. Anticoagulation effects have been reported in canine serum at concentrations as low as 12 ng/mL.</p>
<b>5525B</b>	<b>Fluphenazine Confirmation, Blood</b> <ul style="list-style-type: none"> <li>Fluphenazine</li> </ul>	<p>Steady-state antipsychotic levels following intramuscular decanoate ester dosing every 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.</p> <p>Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL</p>
<b>5525SP</b>	<b>Fluphenazine Confirmation, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Fluphenazine</li> </ul>	<p>Steady-state antipsychotic levels following intramuscular decanoate ester dosing every 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.</p> <p>Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL</p>
<b>9421B</b>	<b>Fluphenazine Screen, Blood</b> <ul style="list-style-type: none"> <li>Fluphenazine</li> </ul>	<p>Steady-state antipsychotic levels following intramuscular decanoate ester dosing every 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.</p> <p>Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL</p>

Changes effective:  
December 4, 2006

**NMS Labs**  
3701 Welsh Road, Willow Grove, PA 19090  
800-522-6671  
nms@nmslabs.com

## REFERENCE COMMENT CHANGES

<b>Test Code</b>	<b>Test Name / Compound</b>	<b>New Reference Comment</b>
9421SP	<b>Fluphenazine Screen, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Fluphenazine</li> </ul>	Steady-state antipsychotic levels following intramuscular decanoate ester dosing every 1 to 2 weeks: 0.9 – 4.0 ng/mL at a dose of 12.5mg, 5 – 7 ng/mL at 25 mg, 5 - 17 ng/mL at 50 mg.  Effective steady-state antipsychotic plasma levels with oral dosing: 0.1 – 3.0 ng/mL
3107U	<b>Nabumetone as Metabolite, Urine</b> <ul style="list-style-type: none"> <li>6-MNA</li> </ul>	No reference data available.
0451B	<b>Aripiprazole, Blood</b> <ul style="list-style-type: none"> <li>Aripiprazole</li> </ul>	Steady state plasma levels in adults following a daily regimen have been reported as: 5 mg - 70 to 126 ng/mL 10 mg - 109 to 216 ng/mL 15 mg - 206 to 278 ng/mL 20 mg - 212 to 574 ng/mL 30 mg - 320 to 585 ng/mL.
0451SP	<b>Aripiprazole, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Aripiprazole</li> </ul>	Steady state plasma levels in adults following a daily regimen have been reported as: 5 mg - 70 to 126 ng/mL 10 mg - 109 to 216 ng/mL 15 mg - 206 to 278 ng/mL 20 mg - 212 to 574 ng/mL 30 mg - 320 to 585 ng/mL.
0451U	<b>Aripiprazole, Urine</b> <ul style="list-style-type: none"> <li>Aripiprazole</li> </ul>	No reference data available.
0486SP	<b>Atomoxetine, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Atomoxetine</li> </ul>	Steady-state plasma levels in adults on a chronic 20 mg twice daily regimen: 35 - 160 ng/mL in extensive metabolizers (normal) and 500 - 915 ng/mL in poor metabolizers (approximately 7% of Caucasian population).
0486U	<b>Atomoxetine, Urine</b> <ul style="list-style-type: none"> <li>Atomoxetine</li> </ul>	No reference data available.
3063SP	<b>Mycophenolic Acid and Metabolite, Serum/Plasma</b> <ul style="list-style-type: none"> <li>Mycophenolic Acid Glucuronide</li> </ul>	Suggested Trough Plasma Concentrations: 15 - 125 mcg/mL.
3795U	<b>Pregabalin, Urine</b> <ul style="list-style-type: none"> <li>Pregabalin</li> </ul>	Between 92 - 99% of a dose is excreted as unchanged drug in the urine.

Changes effective:  
December 4, 2006

**NMS Labs**  
3701 Welsh Road, Willow Grove, PA 19090  
800-522-6671  
nms@nmslabs.com

#### REFERENCE COMMENT CHANGES

<b>Test Code</b>	<b>Test Name / Compound</b>	<b>New Reference Comment</b>
4666B	<b>Duloxetine, Blood</b> <ul style="list-style-type: none"><li>Duloxetine</li></ul>	Steady state trough plasma concentrations after 5 days of oral therapy were: 20 mg twice daily: 4 to 22 ng/mL 30 mg twice daily: 8 to 48 ng/mL 40 mg twice daily: 12 to 60 ng/mL.
4666SP	<b>Duloxetine, Serum/Plasma</b> <ul style="list-style-type: none"><li>Duloxetine</li></ul>	Steady state trough plasma concentrations after 5 days of oral therapy were: 20 mg twice daily: 4 to 22 ng/mL 30 mg twice daily: 8 to 48 ng/mL 40 mg twice daily: 12 to 60 ng/mL.